HUE059777T2 - Lixiszenatid szintézise lánczárással - Google Patents

Lixiszenatid szintézise lánczárással

Info

Publication number
HUE059777T2
HUE059777T2 HUE19715517A HUE19715517A HUE059777T2 HU E059777 T2 HUE059777 T2 HU E059777T2 HU E19715517 A HUE19715517 A HU E19715517A HU E19715517 A HUE19715517 A HU E19715517A HU E059777 T2 HUE059777 T2 HU E059777T2
Authority
HU
Hungary
Prior art keywords
lixisenatide
capping
synthesis
lixisenatide synthesis
Prior art date
Application number
HUE19715517A
Other languages
English (en)
Inventor
Bernd Henkel
Tobias Metzenthin
Manfred Gerken
Wolfgang Fiedler
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62002530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE059777(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of HUE059777T2 publication Critical patent/HUE059777T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C07K1/063General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups for alpha-amino functions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C07K1/062General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups for alpha- or omega-carboxy functions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C07K1/064General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups for omega-amino or -guanidino functions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C07K1/066General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups for omega-amido functions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/10General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
HUE19715517A 2018-04-10 2019-04-10 Lixiszenatid szintézise lánczárással HUE059777T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18166551 2018-04-10

Publications (1)

Publication Number Publication Date
HUE059777T2 true HUE059777T2 (hu) 2022-12-28

Family

ID=62002530

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE19715517A HUE059777T2 (hu) 2018-04-10 2019-04-10 Lixiszenatid szintézise lánczárással

Country Status (15)

Country Link
US (1) US11028123B2 (hu)
EP (1) EP3774838B1 (hu)
JP (1) JP7332620B2 (hu)
KR (1) KR20200142032A (hu)
CN (1) CN112218876A (hu)
AU (1) AU2019250362A1 (hu)
BR (1) BR112020020647A2 (hu)
CA (1) CA3096495A1 (hu)
DK (1) DK3774838T3 (hu)
ES (1) ES2928207T3 (hu)
HU (1) HUE059777T2 (hu)
IL (1) IL277836A (hu)
MX (1) MX2020010715A (hu)
SG (1) SG11202010016QA (hu)
WO (1) WO2019197469A1 (hu)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3774838B1 (en) 2018-04-10 2022-08-10 Sanofi-Aventis Deutschland GmbH Lixisenatide synthesis with capping

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
JP3107488B2 (ja) 1993-09-29 2000-11-06 株式会社資生堂 架橋ヒアルロン酸を用いた徐放性製剤及び塞栓剤
DE69739172D1 (de) 1996-08-08 2009-01-29 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
AR010744A1 (es) 1996-12-09 2000-07-12 Guildford Pharmaceuticals Inc Inhibidores polipropilos de ciclofilina
ES2425559T5 (es) 1997-01-07 2018-02-02 Amylin Pharmaceuticals, Llc Composiciones farmacéuticas que comprenden las exendinas y los agonistas de las mismas
AU749914B2 (en) 1997-08-08 2002-07-04 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
JP2001523688A (ja) 1997-11-14 2001-11-27 アミリン・ファーマシューティカルズ,インコーポレイテッド 新規エキセンジン・アゴニスト化合物
BR9815670A (pt) 1997-11-14 2000-10-17 Amylin Pharmaceuticals Inc Compostos agonistas de exendina
JP2002521319A (ja) 1998-07-23 2002-07-16 メタファー・インコーポレイテッド ポリヒドロキサメートおよびそのアナログのライブラリー
GB9818730D0 (en) * 1998-08-27 1998-10-21 Univ Portsmouth Collections of compounds
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
WO2001072412A1 (de) * 2000-03-28 2001-10-04 Laser- Und Medizin-Technologie Gmbh Berlin Verfahren und vorrichtung zum aufbau und untersuchung von substanzbibliotheken
DE60327771D1 (de) 2002-07-04 2009-07-09 Zealand Pharma As Glp-1 und behandlungsmethode für diabetes
MXPA05003335A (es) 2002-10-02 2005-07-05 Zealand Pharma As Compuestos de exendina-4 estabilizados.
US20050106100A1 (en) 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
US20050176079A1 (en) 2004-02-09 2005-08-11 Chu Yong L. Polypeptide bioconjugates, methods of making the bioconjugates and assays employing the bioconjugates
US20080019911A1 (en) 2005-04-20 2008-01-24 Aimin Xu Method for decreasing blood glucose and improving glucose tolerance using angiopoietin-like protein 4
KR20080026117A (ko) 2005-05-26 2008-03-24 브리스톨-마이어스 스큅 컴퍼니 N-말단 개질된 glp-1 수용체 조절제
DK1891105T3 (da) 2005-06-13 2012-07-16 Imp Innovations Ltd Hidtil ukendte forbindelser og deres påvirkninger på spiseadfærd
RU2429018C2 (ru) 2005-07-06 2011-09-20 Сейкагаку Корпорейшн Гель, полученный из фотосшитой гиалуроновой кислоты с введенным лекарственным средством
CN101357938B (zh) 2007-07-31 2013-07-03 周逸明 固相多肽合成Exenatide的制备方法
WO2009095479A2 (en) 2008-02-01 2009-08-06 Ascendis Pharma As Prodrug comprising a self-cleavable linker
PL2300035T3 (pl) 2008-06-17 2016-04-29 Univ Indiana Res & Tech Corp Mieszani agoniści na bazie GIP do leczenia zaburzeń metabolicznych i otyłości
BRPI1008039A2 (pt) 2009-02-20 2016-10-04 Ipsen Pharma Sas composto, mistura, composição farmacêutica, e, uso de um coposto, de uma mistura ou de uma composição farmacêutica
KR20120087875A (ko) 2009-06-16 2012-08-07 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Gip 수용체-활성 글루카곤 화합물
WO2011012723A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Injectable sustained release compositions comprising a pramipexole prodrug
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
US8507428B2 (en) 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
CN103282054A (zh) 2011-01-03 2013-09-04 弗·哈夫曼-拉罗切有限公司 抗dig抗体和与肽缀合的地高辛配基的复合物的药物组合物
US20130289241A1 (en) 2012-04-26 2013-10-31 Shanghai Ambiopharm, Inc. Method for preparing exenatide
CA2877358A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
PE20150863A1 (es) 2012-06-21 2015-06-11 Univ Indiana Res & Tech Corp Analogos de glucagon que exhiben actividad de receptor de gip
CN103163233B (zh) 2012-07-12 2014-06-25 海南合瑞制药股份有限公司 固相合成胸腺肽α1的28肽阶段的缺失肽及检测方法
WO2014049610A2 (en) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
KR102215175B1 (ko) 2012-11-06 2021-02-15 레스 오삐또 유니베르시테르 드 제네브 모방 펩티드
HUE038748T2 (hu) 2012-12-21 2018-11-28 Sanofi Sa Exendin-4 származékok, mint duális GLP1/GIP- vagy trigonális GLP1/GIP/glukagon-agonisták
MX369770B (es) 2013-11-06 2019-11-21 Zealand Pharma As Compuestos agonistas triples de glucagón-glp-1-gip.
TW201609800A (zh) 2013-12-13 2016-03-16 賽諾菲公司 做為雙重glp-1/升糖素受體促效劑之艾塞那肽-4胜肽類似物
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086732A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues
CN103819553A (zh) * 2013-12-27 2014-05-28 苏贤斌 一种使用固相和液相组合技术制备利西拉来的方法
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
CN104211801A (zh) * 2014-07-25 2014-12-17 杭州诺泰制药技术有限公司 一种制备利西拉来的方法
CN104844706B (zh) 2015-06-10 2018-08-03 成都圣诺生物科技股份有限公司 一种合成利西拉来的方法
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
BR112018008681A2 (pt) * 2015-10-28 2018-10-30 Tufts Medical Center novos polipeptídeos com estabilidade proteolítica melhorada, e métodos para preparar e usar os mesmos
JP6991196B2 (ja) * 2016-03-23 2022-02-03 バッヘン・ホールディング・アクチエンゲゼルシャフト グルカゴン様ペプチドを製造するための方法
WO2017189925A1 (en) 2016-04-28 2017-11-02 C S Bio Co. Methods of preparing peptides
TW201821434A (zh) 2016-10-10 2018-06-16 法商賽諾菲公司 製備包含親脂性修飾的離胺酸側鏈的肽的方法
AR110300A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
BR112020020652A2 (pt) * 2018-04-10 2021-03-02 Sanofi-Aventis Deutschland Gmbh método para clivagem de peptídeos ligados à fase sólida a partir da fase sólida
EP3774838B1 (en) 2018-04-10 2022-08-10 Sanofi-Aventis Deutschland GmbH Lixisenatide synthesis with capping

Also Published As

Publication number Publication date
US11028123B2 (en) 2021-06-08
IL277836A (en) 2020-11-30
US20190330263A1 (en) 2019-10-31
WO2019197469A1 (en) 2019-10-17
CN112218876A (zh) 2021-01-12
MX2020010715A (es) 2021-01-08
JP2021521144A (ja) 2021-08-26
ES2928207T3 (es) 2022-11-16
CA3096495A1 (en) 2019-10-17
SG11202010016QA (en) 2020-11-27
BR112020020647A2 (pt) 2021-02-23
JP7332620B2 (ja) 2023-08-23
EP3774838B1 (en) 2022-08-10
DK3774838T3 (da) 2022-10-31
EP3774838A1 (en) 2021-02-17
KR20200142032A (ko) 2020-12-21
AU2019250362A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
CA185598S (en) Bottle
CA187974S (en) Bottle
CA187321S (en) Bottle
CA193246S (en) Bottle
CA193346S (en) Bottle
CA187265S (en) Bottle
CA186606S (en) Bottle
CA186954S (en) Bottle
CA186846S (en) Bottle
CA185155S (en) Bottle
IL276752B1 (en) Bottle assembly
CA187267S (en) Bottle
CA186845S (en) Bottle
CA186351S (en) Bottle
CA186377S (en) Bottle
IL277836A (en) Synthesis of liquicentide with capping
GB2570794B (en) Capping Assembly
CA185528S (en) Bottle
GB2594366B (en) Capping
GB2580482B (en) Connecting mechanism
GB201800605D0 (en) Capping arrangement
CA186860S (en) Bottle
CA186604S (en) Bottle
CA185314S (en) Bottle
CA185315S (en) Bottle